Dr. Daniel Morgensztern is a medical oncology specialist with the Siteman Cancer Center. He is a Professor of Medicine in the Division of Oncology, Section of Medical Oncology of the Washington University School of Medicine. His clinical expertise lies in the treatment of patients diagnosed with lung cancer, as well as malignant pleural mesothelioma and peritoneal mesothelioma. He is involved in both patient care and clinical research and has published several articles in national journals highlighting population trends in lung cancer diagnosis, as well as reviews and progress of clinical trials for lung cancer treatment.
Education and Career
Dr. Morgensztern earned his medical degree at the Fundacao Tecnico-Educacional Souza Marques, in Brazil, then continued his education with a residency in combined Internal Medicine and Hematology at the State University of Rio De Janeiro. He completed an internship and residency in Internal Medicine at the University of Miami in Miami, Florida, then pursued a fellowship in Hematology-Oncology at the same location.
Following his education, Dr. Morgensztern became an instructor in the Division of Oncology at Washington University School of Medicine (WUSM). He moved on to become a staff physician in the section of Hematology/Oncology at the John Cochran VA Medical Center in St. Louis and an assistant professor in the Division of Oncology at WUMS. He then moved on to become Assistant Professor in the Division of Oncology at Yale University Medical School and Firm Chief of Inpatient Medical Oncology at the Smilow Cancer Center in New Haven, Connecticut. He returned to Washington University School of Medicine in 2013, becoming Professor of the Division of Medical Oncology and Director of Thoracic Oncology.
Dr. Morgensztern also serves as a consultant for AbbVie, Arcus Bioscience, and Eli Lilly and serves on the Data and Safety Monitoring Board for Bristol-Myers Squibb.
Dr. Morgensztern is actively involved in editing a variety of books, journals, and articles, including those listed below:
- Editor, Clinical Lung Cancer, 2020-Present
- National Comprehensive Cancer Network Small Cell Lung Cancer Committee, 2015-Present
- Co-editor, Washington Manual of Oncology, 4th edition 2020
- Editor, Journal of Thoracic Disease, 2016-2018
- Co-editor, DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology Review. Wolters Kluwer, 4th edition, 2016
- Co-editor, Washington Manual of Oncology, 3rd Edition, Wolters Kluwer, 2015
- Associate Editor, DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology Review. Lippincott, Williams and Wilkins, 3rd edition, 2012
- Co-editor, Lung Cancer: A Clinical Guide. Lippincott-Williams and Wilkins, 2008